Characterisation of parathyroid hormone concentration in extremely preterm or very low birthweight infants in routine clinical screening for metabolic bone disease: A service evaluation cohort study.
biochemistry
endocrinology
intensive care units, neonatal
micronutrients
neonatology
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
22
06
2023
received:
02
05
2023
accepted:
25
07
2023
pubmed:
7
8
2023
medline:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
To characterise parathyroid hormone (PTH) concentrations in infants at high risk for metabolic bone disease, in order to assist clinical decisions around the use of PTH for screening. Infants born under 28 weeks' postmenstrual age or with birthweight under 1.5 kg in a tertiary neonatal unit in the UK were included. Clinical guidance was to assess PTH concentration in the first 3 weeks after birth. Clinical information was extracted from prospective records. Sixty-four infants had mean birth gestation of 26 weeks and birthweight of 882 g. Median PTH (sent on median day 18 of life) was 9.2 pmol/L (interquartile range 5.3-17 pmol/L). Sixty-seven per cent of infants had a PTH greater than 7 pmol/L. For 22% of the infants, raised PTH was not accompanied by abnormal phosphate or alkaline phosphatase. Eighty-nine per cent of infants tested were insufficient or deficient for 25-hydroxyvitamin D. Universal screening highlights the high frequency of high PTH in this high-risk population, implying a need for calcium supplementation. A considerable number of infants would not be identified as showing potential signs of metabolic bone disease if the assessment excludes the use of PTH. The high level of 25-hydroxyvitamin D deficiency may be a confounder.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1145Informations de copyright
© 2023 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Rustico SE, Calabria AC, Garber SJ. Metabolic bone disease of prematurity. J. Clin. Transl. Endocrinol. 2014; 1: 85-91.
Chinoy A, Mughal MZ, Padidela R. Metabolic bone disease of prematurity: Causes, recognition, prevention, treatment and long-term consequences. Arch. Dis. Child. Fetal Neonatal Ed. 2019; 104: F560-F566.
Kovacs CS. Bone development and mineral homeostasis in the fetus and neonate: Roles of the calciotropic and phosphotropic hormones. Physiol. Rev. 2014; 94: 1143-1218.
Chinoy A, Mughal MZ, Padidela R. Metabolic bone disease of prematurity - National survey of current neonatal and paediatric endocrine approaches. Acta Paediatr. 2020; 110: 1855-1862.
Holland PC, Wilkinson AR, Diez J, Lindsell DRM. Prenatal deficiency of phosphate, phosphate supplementation, and rickets in very-low-birthweight infants. Lancet 1990; 335: 697-701.
Moreira A, Swischuk L, Malloy M, Mudd D, Blanco C, Geary C. Parathyroid hormone as a marker for metabolic bone disease of prematurity. J. Perinatol. 2014; 34: 787-791.
Matejek T, Navratilova M, Zaloudkova L et al. Parathyroid hormone - Reference values and association with other bone metabolism markers in very low birth weight infants - Pilot study. J. Matern. Fetal Neonatal Med. 2019; 32: 2860-2867.
Mitchell SM, Rogers SP, Hicks PD, Hawthorne KM, Parker BR, Abrams SA. High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr. 2009; 9: 1-7.
Mohamed M, Kamleh M, Muzzy J, Groh-Wargo S, Abu-Shaweesh J. Association of protein and vitamin D intake with biochemical markers in premature osteopenic infants: A case-control study. Front. Pediatr. 2020; 8: 546544.
Rayannavar A, Calabria AC. Screening for metabolic bone disease of prematurity. Semin. Fetal Neonatal Med. 2020; 25: 101086.
Abrams SA, Bhatia JJS, Corkins MR et al. Calcium and vitamin D requirements of enterally fed preterm infants. Pediatrics 2013; 131: e1676-83.
Taylor SN, Wahlquist A, Wagner CL, Ramakrishnan V, Ebeling M, Hollis BW. Functional indicators of vitamin D adequacy for very low birth weight infants. J. Perinatol. 2018; 38: 550-556.
Hung YL, Chen PC, Jeng SF et al. Serial measurements of serum alkaline phosphatase for early prediction of osteopaenia in preterm infants. J. Paediatr. Child Health 2011; 47: 134-139.
Backström MC, Kouri T, Kuusela AL et al. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Paediatr. 2000; 89: 867-873.
Tkach EK, White AM, Dysart KC et al. Comparison of intact parathyroid hormone, alkaline phosphatase, phosphate levels for diagnosing severe metabolic bone disease in infants with severe bronchopulmonary dysplasia. Am. J. Perinatol. 2017; 34: 1199-1204.
British Association of Perinatal Medicine. The Provision of Parenteral Nutrition Within Neonatal Services - A Framework for Practice. 2016.
Levene I, McCormick K. Improved growth of extremely and very preterm babies: Evaluation of a quality-of-care initiative. J. Paediatr. Child Health 2020; 56: 444-449.
National Neonatal Audit Programme. National Neonatal Audit Programme - Individual Unit Data. Available from: https://nnap.rcpch.ac.uk/spine.aspx
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann. Intern. Med. 2007; 147: 573-577.
Minieri M, Leoni BD, Bellincampi L et al. Serum iPTH range in a reference population: From an integrated approach to vitamin D prevalence impact evaluation. Clin. Chim. Acta 2021; 521: 1-8.
Adeli K, Higgins V, Trajcevski K, White-Al Habeeb N. The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper. Crit. Rev. Clin. Lab. Sci. 2017; 54: 358-413.